BioSpace News Archive

OpRegen ® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy

Femasys Inc. today announced the initiation and first patient treated in a pivotal trial evaluating FemaSeed, a first in class, localized directional insemination product candidate for infertility.

Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2021 financial results will be released on Tuesday, August 3, 2021, after the close of the stock market.

Agilent Technologies Inc. (NYSE: A) today announced the availability of an optimized and verified eMethod for PFAS Analysis in Water by LC/TQ for testing per- and polyfluoroalkyl substances (PFAS) in drinking and surface water using liquid chromatography and mass spectrometry.

– MARIO-3 Phase 2 study evaluating eganelisib added to standard of care Tecentriq ® and Abraxane ® regimen in frontline triple negative breast cancer (TNBC)–

NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® device has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for treating the symptoms of fibromyalgia in adults.

Stereotaxis today announced that it will release financial results for its 2021 second quarter on Tuesday, August 10, 2021 before the open of the U.S. financial markets.

Brian Stolz Joins as Chief People Officer, Diana King as VP of Customer Support, and Jordan Neysmith as VP of Engineering

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States focused on early cancer screening and detection as well as cancer treatment, pre-announced that it has experienced strong growth in test volume in the first half year of 2021, with total number of paid customers and testing volume increasing almost 110% compared with the same period in 2020.

Immuneering Corporation, a private biopharmaceutical company advancing a robust pipeline of oncology and neuroscience drug candidates that are designed to uniquely disrupt cellular signaling dynamics, announced the appointment of Michael Bookman to the newly created position of General Counsel and Secretary, effective immediately.